Advanced Therapy for Hepatitis CGeoffrey W. McCaughan, John McHutchison, Jean-Michel Pawlotsky Hepatologists, both researchers and front-line clinicians, now have a comprehensive guide to the treatment of patients with the HCV virus. This book focuses mainly on the efficacy and clinical use of antiviral therapies, including the use of antivirals post liver transplantation and in the presence of the HIV virus. It also explores the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs. A 'late-breaking information' chapter contains the most recent trial results on the latest antiviral drugs. |
Contents
| 3 | |
Mechanisms of Action of Antiviral Drugs | 26 |
Pharmacology and Mechanisms of Action | 46 |
Pharmacology and Mechanisms of Action | 69 |
Measuring Antiviral Responses | 9 |
Genotype 1 Standard Treatment | 18 |
Side Effects and Dose Adjustments | 24 |
Individually Tailored Treatment Strategies | 24 |
Hepatitis C Genotype 4 Therapy Progress | 30 |
Formulations in HCV4 Infections | 48 |
Antivirals in Acute Hepatitis C | 76 |
Antivirals in Cirrhosis and Portal | 85 |
Treatment of Recurrent Hepatitis C Following | 100 |
Antiviral Treatment in Chronic Hepatitis C | 39 |
Cytopenias How they Limit Therapy | 13 |
The Problem of Insulin Resistance and | 29 |
Genotype 1 Relapsers and Nonresponders | 11 |
Conclusion | 19 |
Altered Dosage or Durations of Current | 4 |
Conclusions | 13 |
Therapy | 22 |
HIV and Hepatitis C Coinfection | 42 |
HCV and Racial Differences | 56 |
Treatment | 56 |
New Horizons IL28 Directacting Antiviral | 56 |
Cyclophilin Inhibitors | 46 |
Other editions - View all
Advanced Therapy for Hepatitis C Geoffrey W. McCaughan,John McHutchison,Jean-Michel Pawlotsky No preview available - 2011 |
Common terms and phrases
12 weeks 24 weeks 48 weeks acute hepatitis African Americans alfa-2b plus ribavirin antiviral activity antiviral therapy associated baseline cell chronic hepatitis cirrhosis clinical trials combination therapy cryoglobulinemia cyclophilin drug efficacy Engl fibrosis Gastroenterol Gastroenterology genome genotype 1 HCV genotype 1 infection genotype 1 patients HCV genotype HCV replication hepatitis C genotype hepatitis C virus Hepatol Hepatology infected patients inhibition insulin resistance interferon alfa-2b interferon and ribavirin liver disease liver transplantation McHutchison JG monotherapy mutations non-responders NS5A NS5B nucleoside patients with chronic patients with genotype Peg-IFN alfa-2b Peg-IFN and RBV peginterferon alfa-2a peginterferon and ribavirin pegylated interferon phase polymerase inhibitor protease inhibitor protein randomized recurrent hepatitis reduced regimen relapse replicon ribavirin ribavirin dose ribavirin therapy Shiffman ML sustained virologic response SVR rates telaprevir treatment duration treatment of chronic treatment-naïve vasculitis versus viral load Virol virus genotype virus infection vitro week 12 weight-based